These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 31164306)
1. Use of the 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) in an Australian Indigenous paediatric population does not alter the prevalence of nontypeable Haemophilus influenzae without the protein D gene. Beissbarth J; Smith-Vaughan HC; Harris TM; Binks MJ; Leach AJ Vaccine; 2019 Jul; 37(30):4089-4093. PubMed ID: 31164306 [TBL] [Abstract][Full Text] [Related]
2. Reduced middle ear infection with non-typeable Haemophilus influenzae, but not Streptococcus pneumoniae, after transition to 10-valent pneumococcal non-typeable H. influenzae protein D conjugate vaccine. Leach AJ; Wigger C; Hare K; Hampton V; Beissbarth J; Andrews R; Chatfield M; Smith-Vaughan H; Morris PS BMC Pediatr; 2015 Oct; 15():162. PubMed ID: 26482232 [TBL] [Abstract][Full Text] [Related]
3. The Effect of the 10-Valent Pneumococcal Nontypeable Haemophilus influenzae Protein D Conjugate Vaccine on H. influenzae in Healthy Carriers and Middle Ear Infections in Iceland. Sveinsdóttir H; Björnsdóttir JB; Erlendsdóttir H; Hjálmarsdóttir MÁ; Hrafnkelsson B; Haraldsson Á; Kristinsson KG; Haraldsson G J Clin Microbiol; 2019 Jul; 57(7):. PubMed ID: 31068412 [TBL] [Abstract][Full Text] [Related]
4. Reduced nontypeable Haemophilus influenzae lower airway infection in children with chronic endobronchial suppuration vaccinated with the 10-valent pneumococcal H. influenzae protein D conjugate vaccine. Hare KM; Smith-Vaughan HC; Leach AJ; Pizzutto SJ; McCallum GB; Chang AB Vaccine; 2018 Mar; 36(13):1736-1742. PubMed ID: 29478754 [TBL] [Abstract][Full Text] [Related]
5. General health, otitis media, nasopharyngeal carriage and middle ear microbiology in Northern Territory Aboriginal children vaccinated during consecutive periods of 10-valent or 13-valent pneumococcal conjugate vaccines. Leach AJ; Wigger C; Beissbarth J; Woltring D; Andrews R; Chatfield MD; Smith-Vaughan H; Morris PS Int J Pediatr Otorhinolaryngol; 2016 Jul; 86():224-32. PubMed ID: 27260611 [TBL] [Abstract][Full Text] [Related]
8. Impact of protein D-containing pneumococcal conjugate vaccines on non-typeable Haemophilus influenzae acute otitis media and carriage. Clarke C; Bakaletz LO; Ruiz-Guiñazú J; Borys D; Mrkvan T Expert Rev Vaccines; 2017 Jul; 16(7):1-14. PubMed ID: 28571504 [TBL] [Abstract][Full Text] [Related]
9. Nasopharyngeal carriage of otitis media pathogens in infants receiving 10-valent non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10), 13-valent pneumococcal conjugate vaccine (PCV13) or a mixed primary schedule of both vaccines: A randomised controlled trial. Beissbarth J; Wilson N; Arrowsmith B; Binks MJ; Oguoma VM; Lawrence K; Llewellyn A; Mulholland EK; Santosham M; Morris PS; Smith-Vaughan HC; Cheng AC; Leach AJ Vaccine; 2021 Apr; 39(16):2264-2273. PubMed ID: 33766422 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of the indirect impact of the 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine in a cluster-randomised trial. Rinta-Kokko H; Palmu AA; Ruokokoski E; Nieminen H; Moreira M; Schuerman L; Borys D; Jokinen J PLoS One; 2022; 17(1):e0261750. PubMed ID: 34986178 [TBL] [Abstract][Full Text] [Related]
11. PHiD-CV induces anti-Protein D antibodies but does not augment pulmonary clearance of nontypeable Haemophilus influenzae in mice. Siggins MK; Gill SK; Langford PR; Li Y; Ladhani SN; Tregoning JS Vaccine; 2015 Sep; 33(38):4954-61. PubMed ID: 26212006 [TBL] [Abstract][Full Text] [Related]
12. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against all respiratory tract infections in children under two years of age. Karppinen S; Toivonen L; Schuez-Havupalo L; Teros-Jaakkola T; Waris M; Auranen K; Palmu AA; Peltola V Vaccine; 2019 May; 37(22):2935-2941. PubMed ID: 31027929 [TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) co-administered with DTPa vaccine in Japanese children: A randomized, controlled study. Iwata S; Kawamura N; Kuroki H; Tokoeda Y; Miyazu M; Iwai A; Oishi T; Sato T; Suyama A; François N; Shafi F; Ruiz-Guiñazú J; Borys D Hum Vaccin Immunother; 2015; 11(4):826-37. PubMed ID: 25830489 [TBL] [Abstract][Full Text] [Related]
14. Effectiveness of pneumococcal Haemophilus influenzae protein D conjugate vaccine against pneumonia in children: A cluster-randomised trial. Kilpi TM; Jokinen J; Puumalainen T; Nieminen H; Ruokokoski E; Rinta-Kokko H; Traskine M; Lommel P; Moreira M; Ruiz-Guinazu J; Borys D; Schuerman L; Palmu AA Vaccine; 2018 Sep; 36(39):5891-5901. PubMed ID: 30145098 [TBL] [Abstract][Full Text] [Related]
15. Effectiveness of the 10-Valent Pneumococcal Nontypeable Haemophilus influenzae Protein D-Conjugated Vaccine (PHiD-CV) Against Carriage and Acute Otitis Media-A Double-Blind Randomized Clinical Trial in Finland. Vesikari T; Forsten A; Seppä I; Kaijalainen T; Puumalainen T; Soininen A; Traskine M; Lommel P; Schoonbroodt S; Hezareh M; Moreira M; Borys D; Schuerman L J Pediatric Infect Dis Soc; 2016 Sep; 5(3):237-248. PubMed ID: 27125273 [TBL] [Abstract][Full Text] [Related]
16. Otitis media outcomes of a combined 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine and 13-valent pneumococcal conjugate vaccine schedule at 1-2-4-6 months: PREVIX_COMBO, a 3-arm randomised controlled trial. Leach AJ; Mulholland EK; Santosham M; Torzillo PJ; McIntyre P; Smith-Vaughan H; Wilson N; Arrowsmith B; Beissbarth J; Chatfield MD; Oguoma VM; Morris PS BMC Pediatr; 2021 Mar; 21(1):117. PubMed ID: 33685411 [TBL] [Abstract][Full Text] [Related]
17. Otitis media in children vaccinated during consecutive 7-valent or 10-valent pneumococcal conjugate vaccination schedules. Leach AJ; Wigger C; Andrews R; Chatfield M; Smith-Vaughan H; Morris PS BMC Pediatr; 2014 Aug; 14():200. PubMed ID: 25109288 [TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and Safety of 10-valent Pneumococcal Nontypeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Administered to Children With Sickle Cell Disease Between 8 Weeks and 2 Years of Age: A Phase III, Open, Controlled Study. Sirima SB; Tiono A; Gansané Z; Siribié M; Zongo A; Ouédraogo A; François N; Strezova A; Dobbelaere K; Borys D Pediatr Infect Dis J; 2017 May; 36(5):e136-e150. PubMed ID: 28403055 [TBL] [Abstract][Full Text] [Related]
19. Effects of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D-conjugate vaccine on nasopharyngeal bacterial colonization in young children: a randomized controlled trial. van den Bergh MR; Spijkerman J; Swinnen KM; François NA; Pascal TG; Borys D; Schuerman L; Ijzerman EP; Bruin JP; van der Ende A; Veenhoven RH; Sanders EA Clin Infect Dis; 2013 Feb; 56(3):e30-9. PubMed ID: 23118268 [TBL] [Abstract][Full Text] [Related]
20. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial. Palmu AA; Jokinen J; Borys D; Nieminen H; Ruokokoski E; Siira L; Puumalainen T; Lommel P; Hezareh M; Moreira M; Schuerman L; Kilpi TM Lancet; 2013 Jan; 381(9862):214-22. PubMed ID: 23158882 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]